DALDOT, LLC
Co-Founder | CTO | 2018-2021
Overview
In 2018, I co-founded Daldot, LLC with my partner, Ashley Zahabian. Daldot started as a company focused on tracking macronutrient intake via a wearable sensor. We first aimed to study the composition of interstitial fluid (ISF), a sub-dermal biological fluid that transports nutrients and other important biological analytes. Since continuous glucose monitors use ISF to track changes in blood glucose, we hypothesized that we could track other macronutrients using this fluid.
Our Journey
We raised $50,000 USD to conduct a preliminary study concerning the metabolic analysis of ISF. At the time, Daldot was one of few teams around the world to both obtain and study the full metabolic composition of ISF. After the preliminary study, we decided to pivot to monitoring biomarkers of sepsis for early detection. Earlier detection of sepsis enables clinicians to quickly administer treatment and rapidly perform ICU transfers for septic patients, thus decreasing overall costs, complication rates, and septic mortality.
In 2019, following this preliminary study, we recruited a scientific board with expertise around aptamers (short, single-stranded DNA/RNA that can bind to a specific molecule), aptamer based electrochemical (EAB) sensors, and epidemiology. The goal was to develop a wearable patch that could extract small amounts of ISF continuously, detect and measure target molecules, and report concentration levels and diagnostic data back to software. Daldot worked with professors at Columbia University to develop aptamers that targeted our markers and John Hopkins to test the E-AB sensing platform. Our goal was to develop commercially available wearable patches that could detect signs of sepsis through ISF extraction.
Acquisition
On August 10th, 2021, Daldot was acquired by Nutromics. Below is the official statement:
Nutromics Completes Acquisition of Daldot
August 10th, 2021
Nutromics
Nutromics is an Australian MedTech company poised to revolutionize healthcare through Continuous Molecular Monitoring (CMM). The company is developing a very innovative technology which, put simply, is a molecular sensor that can track drugs, metabolites, hormones, and proteins continuously and in real time (just like Continuous Glucose Monitors do with glucose). The holy grail in biosensing has always been a platform technology with capabilities to monitor any target continuously and in real time. We’ve all seen the enormous impact Continuous Glucose Monitors (CGM) are having in the diabetic market. Nutromics’ CMM biosensor platform is the next evolution of CGM technology and will solve some of the biggest healthcare challenges we face today in the fields of Therapeutic Drug Monitoring, chronic disease prevention, chronic disease management and acute diseases.
Daldot
Daldot is a U.S. based company that is developing wearable technology that has the ability to monitor diagnostic and prognostic markers of disease, along with different drugs, with high-frequency and in real-time. This enables clinicians to make better and more timely treatment decisions. Additionally, Daldot’s technology aims to enable patients of different diseases, such as sepsis, to monitor their health from home or in outpatient settings.
Combination to Quicken Innovation
After initial introductions, both companies found that they had a strong alignment in their mission and objectives for change in healthcare and discussions soon began on how the companies could work together effectively to help solve some of the biggest challenges in healthcare. Daldot’s research was a natural fit for Nutromics’ technology and the purchase of Daldot’s key assets will help Nutromics in furthering the understanding of interstitial fluid, its composition and as a biofluid of interest for its technology. As part of the purchase, both of Daldot’s founders will advise Nutromics on the innovative research undertaken by Daldot and transfer critical expertise and know-how to Nutromics.
